Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
By Madhukar H. Trivedi, A. Rush, S. Wisniewski, A. Nierenberg, D. Warden, Louise Ritz, G. Norquist, R. Howland, B. Lebowitz, P. McGrath and 4 more. American Journal of Psychiatry, 2006
3,689 citations recorded by the source corpus.
Subfields: Experimental and Cognitive Psychology, Pharmacology, Social Psychology
View Paper: https://www.semanticscholar.org/paper/24819228db9f3e178230ddce56c9571b1ef2c980
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Experimental and Cognitive Psychology
- F. Frohlich
- Justin Riddle
- Emre Kıcıman
- John B. Torous
- E. Nestler
- Diego A. Pizzagalli
- V. Krishnan
- M. de Choudhury
In Pharmacology
- G. Sanacora
- Justin Riddle
- F. Frohlich
- E. Nestler
- Maurizio Fava
- Todd D. Gould
- Diego A. Pizzagalli
- V. Krishnan
In Social Psychology
- Emre Kıcıman
- John B. Torous
- Koustuv Saha
- Justin Riddle
- E. Nestler
- Diego A. Pizzagalli
- V. Krishnan
- Richard A. Bryant
Citations in the corpus
- Neuroinflammation and depression: A review (2020, background): “…considering that only one-third of patients suffering from MDD achieve complete remission of symptoms after a single antidepressant treatment (Trivedi et al., 2006) and that the remission rate increases up to 60% after two different antidepressant trials (Rush et al., 2006), it can be…”
- Glutamate NMDA receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure (2011, neutral): “Despite a wide range of antidepressants available, only one third of the patients show significant mood improvement in response to an initial antidepressant treatment (2).”
- A Social Media Study on the Effects of Psychiatric Medication Use (2019, background): “Further, in psychiatry, medications are still prescribed by trial-anderror, or based on side effect profiles of these medications (Trivedi et al. 2006).”
- The Bidirectional Relationship of Depression and Inflammation: Double Trouble (2020, background): “…the virtual absence of any depressive symptoms and return to the premorbid state, termed remission, in approximately 50% of previously untreated depressed patients (Dunlop et al., 2017) and in 28% in a more heterogeneous mix of “real-world” patients in an effectiveness study (Trivedi et al., 2006).”
- Toward a Neurobiology of Unrealistic Optimism (2012, methodology): “In addition, a control group of participants were administered Citalopram (a Selective Serotonin Reuptake Inhibitor frequently prescribed for the treatment of depression; Trivedi et al., 2006) instead of l-DOPA.”
- Linking Molecules to Mood: New Insight Into the Biology of Depression (2010, positive): “An important insight gained from everyday clinical practice is the observation that monoamine reuptake inhibitors and other modulators of monoaminergic function improve symptoms in ~50% of depressed patients and produce a remission in 30-40% of patients (28).”
- Glutamate Receptor Ion Channels: Structure, Regulation, and Function (2010, background): “However, all treatments show poor efficacy in as many as half of the patients (Insel, 2006; Trivedi et al., 2006), and require multiple weeks of treatment before a substantial benefit is realized (Anderson et al.”
- Exercise as a treatment for depression: A meta-analysis. (2016, background): “Research points to the importance of maximizing the response to treatment as early as possible due to declining prognosis with depression duration and failed treatment responses (NICE, 2013; Trivedi et al., 2006).”